Skip to main content

Table 1 Clinical characteristics at baseline visit by number of previous bDMARDs

From: Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors—data from a large national quality register

 TotalBionaïve1 previous bDMARD≥ 2 previous bDMARDs
Number of patients (%)2716453 (16.7)741 (27.3)1522 (56)
Female sex (%)2176 (80.1)325 (71.7)599 (80.8)1252 (82.3)
Age at treatment start (years); mean (SD)59.3 (13.3)61.7 (14.0)60.7 (12.9)57.8 (13.0)
Duration of RA at treatment start (years); mean (SD)14.2 (11.4)9.5 (11.1)14.4 (11.8)15.5 (10.8)
Intravenous treatment1365 (50.3%)194 (42.8%)381 (51.8%)790 (52.1%)
Subcutaneous treatment1338 (49.3%)257 (57.0%)355 (48.2%)726 (47.9%)
ESR (mm 1st h); median (IQR)23 (11–42)23 (12–42)23.5 (12–40.25)22 (10–41)
CRP (mg/l); median (IQR)9 (3.5–23)11 (5–24)8 (3.48–23)8 (3–22)
DAS28; mean (SD)4.98 (1.29)5.01 (1.23)4.93 (1.28)4.99 (1.31)
DAS28-CRP; mean (SD)4.66 (1.13)4.64 (1.14)4.57 (1.13)4.70 (1.13)
VAS pain (0–100); mean (SD)60 (23)58 (24)59 (23)62 (22)
VAS global (0–100); mean (SD)60 (22)56 (23)60 (23)62 (22)
Swollen joint count (0–28); median (IQR)5 (2–9)6 (3–10)5 (2–8)5 (2–9)
Tender joint count (0–28); median (IQR)6 (3–10)6 (2–11)6 (3–10)6 (3–11)
HAQ-DI (0–3); mean (SD)1.32 (0.63)1.16 (0.63)1.30 (0.65)1.37 (0.62)
Physicians global (0–4); median (IQR)2 (2–3)2 (2–3)2 (2–3)2 (2–3)
Current methotrexate1288 (57%)196 (55%)373 (61%)719 (55%)
Current glucocorticoids1316 (49%)176 (39%)345 (47%)795 (52%)
Glucocorticoids dose in mg, prednisolone equivalent; mean (SD)7.5 (4.2)7.6 (3.9)6.9 (4.0)7.8 (4.3)
Current csDMARD1489 (55%)237 (52%)425 (57%)827 (54%)
  1. Missing data: Duration of RA at treatment start (years), 17; intravenous/subcutaneous treatment, 13; ESR, 714; CRP, 580; DAS 28, 921; CRP, 811; VAS pain, 748; VAS global, 711; swollen joint count, 624; tender joint count, 625; HAQ-DI, 825; physician global, 711; current methotrexate, 439